Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Still’s disease is a rare rheumatic condition. This condition is characterized by biological and clinical symptoms such as high spiking fever, joint swelling, muscle pain, sore throat, increased number of white cells (leukocytes, especially neutrophils), and biological hepatitis. Treatment for still’s disease can be classified into 2 categories, namely symptomatic treatments and effective therapies. Symptomatic treatments can be initiated immediately, even when the diagnosis has not been established whereas, effective therapies are designed to treat the condition more efficiently to eradicate the symptoms of the disease.

According to a study published in The American Journal of Medicine, the treatment of still’s disease has been largely derived from retrospective data and case reports. While mild cases can be treated with NSAIDs (Nonsteroidal Anti-inflammatory Drugs), more than 80% of still’s disease patients need the use of corticosteroids and do not achieve remission. There is no such known risk factor that develops the Still’s disease, however, it is assumed that it is caused due to over activation of IL-1 (Interleukin-1) in the body.

The rising demand for specific new treatments and the emergence of drugs for still’s disease are expected to drive the still’s disease treatment market growth during the forecast period. For instance, as per the U.S. Food and Drug Administration (FDA), Canakinumab (Ilaris) can be indicated to all patients older than 2 years with Still's disease.

Still’s Disease Treatment Market - Impact of Coronavirus (Covid-19) Pandemic

Still’s disease treatment market is hugely affected due to the outbreak of COVID-19, as it is becoming difficult for researchers to conduct researches during this pandemic situation. People with rheumatic diseases such as Still's disease are more prone to getting infected with the coronavirus. Thus, majority of the vendors are concentrating on developing strategies to help patients with still’s disease to remain agile during the global disruptions due to COVID-19 pandemic. In addition, many government bodies across the globe are taking decisions such as new regulations to deal with the current crisis.

The all-inclusive version of the report will include the impact of COVID-19 and the probable changes in the future outlook of the industry, by taking into account the technological, social, political, and economical parameters.

The still’s disease treatment market is estimated to be valued at US$ 1,539.4 million in 2020 and is expected to rise at a CAGR of 4.49% during the forecast period (2020-2027).

Figure 1. Still’s Disease Treatment Market Share (%) Analysis, By Route of Administration, 2020

Still’s Disease Treatment  | Coherent Market Insights

An increase in the number of mergers & acquisitions and drug launches is expected to propel growth of the still’s disease treatment market

Key players in the market are involved in mergers & acquisitions to develop advanced drugs and treatment, and launch them in the still’s disease treatment market. The drug launches in the industry is estimated to significantly boost the market growth and create lucrative growth opportunities in the overall market during the forecast period.

For instance, in July 2018, SOBI launched a third-line treatment, Kineret drug for the treatment of adult-onset still's disease (AOSD). This new therapy is indicated when the patient does not respond to Disease-modifying antirheumatic drugs (DMARDs)  and corticosteroids, and fail to respond to methotrexate. The drug is currently available in the U.K. for Cryopyrin-associated periodic syndromes (CAPS) and rheumatoid arthritis (RA).

Furthermore, companies are adopting several strategies such as license agreements and partnerships to hold a strong position in the global industry. For instance, in July 2019, Aevi Genomic Medicine entered into a license agreement with AstraZeneca for phase II trials of MEDI2338, which is a fully human mAb (monoclonal antibody) that targets IL-18 (interleukin 18). The company has planned to initially develop MEDI2338 for AOSD (adult-onset Still's disease), which is a rare and orphan rheumatological disease with presently no approved biologic therapies in the U.S.

Still’s Disease Treatment Market - Restraints

Unavailability of specific therapeutics for still’s disease condition is considered to be one of the potential restraints affecting the market growth. For instance, the treatment for still’s disease is directed towards the use of anti-inflammatory drugs such as aspirin and other nonsteroidal drugs (NSAIDs). In some cases, cortisone medications such as prednisone are used to treat the condition. Other factors such as increasing number of generic therapeutics, product recalls, and patent expiration of licenses & various drugs are likely to hamper the market growth.

request-sample

Still’s Disease Treatment Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 1,539.4 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 4.49% 2027 Value Projection: US$ 2,093.8 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Treatment: Tocilizumab, Canakinumab, Anakinra, Pain Management, Corticosteroids Therapy, Other.
  • By Route of Administration: Injectable, Oral.
  • By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Pharmacies.
Companies covered:

AB2 Bio Ltd., F. Hoffmann-La Roche Ltd, Novartis AG, Swedish Orphan Biovitrum AB, Jubilant Life Sciences Ltd, Vintage Labs, Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd, Mylan N.V., Horizon Therapeutics plc, Sun Pharmaceutical Industries Ltd, Zydus Cadila, Amneal Pharmaceuticals LLC, Dr Reddy's Laboratories Ltd., and Fresenius Kabi AG.

Growth Drivers:
  • Increasing prevalence of Still’s disease across the globe
  • Increasing investments in research & development to develop novel treatment
Restraints & Challenges:
  • Introduction of generics and patent expiration of branded drugs
  • Lack of healthcare budget in low- and middle-income countries

Still’s Disease Treatment Market – Regional Analysis

Europe region accounted for the largest share in the still’s disease treatment market in 2019, owing to the increasing focus of key players on research & development and European Commission (EC) approvals in the market. For instance, in April 2018, Swedish Orphan Biovitrum AB announced that Kineret (anakinra) is approved by the EC for the treatment of still’s disease. Kineret is indicated for adults, children, adolescents, and infants aged 8 months and above with at least 10kg bodyweight for the treatment of Still’s disease. This also includes AOSD and SJIA with active systemic features of moderate to high disease activity.

The U.S. market followed the same. In June 2020, the U.S. FDA approved Switzerland-based Novartis’s Ilaris injection for the treatment of active still’s disease. This approval also includes treatment for Adult-Onset Still’s Disease (AOSD). The Ilaris injection was formerly approved for SJIA (Systemic Juvenile Idiopathic Arthritis) in patients aged 2 years and above.

The Asia Pacific region is witnessing a promising growth in the global still’s disease treatment market, owing to initiatives taken by key players and approvals for the treatment of adult still’s disease. For instance, in May 2019, Chugai Pharmaceutical Co., Ltd., a subsidiary of F. Hoffmann-La Roche Ltd.  received expanded approval from the MHLA (Ministry of Health Labor and Welfare) in Japan for Actemra (tocilizumab) for the treatment of adult Still’s disease.

Figure 2. Still’s Disease Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2027

Still’s Disease Treatment  | Coherent Market Insights

Global Still’s Disease Treatment Market - Competitive Landscape

Key players operating in the Still’s disease treatment market include AB2 Bio Ltd., F. Hoffmann-La Roche Ltd, Novartis AG, Swedish Orphan Biovitrum AB, Jubilant Life Sciences Ltd, Vintage Labs, Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd, Mylan N.V., Horizon Therapeutics plc, Sun Pharmaceutical Industries Ltd, Zydus Cadila, Amneal Pharmaceuticals LLC, Dr Reddy's Laboratories Ltd., and Fresenius Kabi AG.

Still’s disease, also known as adult-onset Still's disease (AOSD), is a rare type of inflammatory disorder associated with joint pain, rash, and fevers. This devastating condition may lead to long-term chronic arthritis and can result in permanent disabilities. Still's disease is related to the rash that does not itch and high spiking fever. This disorder can destroy affected joints, mainly the wrists. The treatment of Still’s disease involves medications that help inflammation.

Market Dynamics

The increase in funding for research and development to develop novel therapies and treatment coupled with increasing prevalence of Still’s disease are the major factors boosting growth of the global still’s disease treatment market. For instance, according to WebMD, Still's disease is more prevalent in women and affects less than 1 in 100,000 people across the globe develop Still's or adult-onset still’s each year.

Moreover, the emergence of drugs for the treatment of complications related to Still's disease is another factor propelling the market growth. For instance, in July 2020, the U.S. Food and Drug Administration (FDA) expanded the use of Canakinumab (Ilaris) for all patients with active Still's disease older than 2 years. Therefore, the drug can now be used for the adult-onset Still's disease (AOSD), which was previously approved for only juvenile-onset Still's disease.

However, the lack of healthcare finance in some low- and middle-income countries and patent expiration of drugs are some of the major factors restricting growth of the global still’s disease treatment market.

Key features of the study:

  • This report provides in-depth analysis of the global still’s disease treatment market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2020-2027, considering 2019 as the base year
  • It elucidates potential revenue opportunity across different segments and explains the attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global Still’s disease treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
  • Key players covered as a part of this study include F. Hoffmann-La Roche Ltd, Swedish Orphan Biovitrum AB, Novartis AG, Jubilant Life Sciences Ltd, AB2 Bio Ltd., Hikma Pharmaceuticals PLC, Dr Reddy's Laboratories Ltd., Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Mylan N.V., Zydus Cadila, Horizon Therapeutics plc, Amneal Pharmaceuticals LLC, Fresenius Kabi AG., and Vintage Labs
  • Insights from this report would allow marketers and management authorities of companies to make an informed decision with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global still’s disease treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for Still’s disease treatment market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Still’s Disease Treatment Market, By Treatment:
    • Pain Management
    • Corticosteroids Therapy
    • Tocilizumab
    • Canakinumab
    • Anakinra
    • Others
  • Global Still’s Disease Treatment Market, By Route of Administration:
    • Injectable
    • Oral
  • Global Still’s Disease Treatment Market, By Distribution Channel:
    • Retail Pharmacies
    • Hospital Pharmacies
    • Online Pharmacies
  • Global Still’s Disease Treatment Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Treatment:
        • Pain Management
        • Corticosteroids Therapy
        • Tocilizumab
        • Canakinumab
        • Anakinra
        • Others
      • By Route of Administration:
        • Injectable
        • Oral
      • By Distribution Channel:
        • Retail Pharmacies
        • Hospital Pharmacies
        • Online Pharmacies
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Treatment:
        • Pain Management
        • Corticosteroids Therapy
        • Tocilizumab
        • Canakinumab
        • Anakinra
        • Others
      • By Route of Administration:
        • Injectable
        • Oral
      • By Distribution Channel:
        • Retail Pharmacies
        • Hospital Pharmacies
        • Online Pharmacies
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Treatment:
        • Pain Management
        • Corticosteroids Therapy
        • Tocilizumab
        • Canakinumab
        • Anakinra
        • Others
      • By Route of Administration:
        • Injectable
        • Oral
      • By Distribution Channel:
        • Retail Pharmacies
        • Hospital Pharmacies
        • Online Pharmacies
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Treatment:
        • Pain Management
        • Corticosteroids Therapy
        • Tocilizumab
        • Canakinumab
        • Anakinra
        • Others
      • By Route of Administration:
        • Injectable
        • Oral
      • By Distribution Channel:
        • Retail Pharmacies
        • Hospital Pharmacies
        • Online Pharmacies
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Treatment:
        • Pain Management
        • Corticosteroids Therapy
        • Tocilizumab
        • Canakinumab
        • Anakinra
        • Others
      • By Route of Administration:
        • Injectable
        • Oral
      • By Distribution Channel:
        • Retail Pharmacies
        • Hospital Pharmacies
        • Online Pharmacies
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
      • By Treatment:
        • Pain Management
        • Corticosteroids Therapy
        • Tocilizumab
        • Canakinumab
        • Anakinra
        • Others
      • By Route of Administration:
        • Injectable
        • Oral
      • By Distribution Channel:
        • Retail Pharmacies
        • Hospital Pharmacies
        • Online Pharmacies
  • Company Profiles
    • F. Hoffmann-La Roche Ltd.
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Swedish Orphan Biovitrum AB
    • Novartis AG
    • Jubilant Life Sciences Ltd
    • AB2 Bio Ltd.
    • Hikma Pharmaceuticals PLC
    • Dr Reddy's Laboratories Ltd.
    • Teva Pharmaceutical Industries Ltd
    • Sun Pharmaceutical Industries Ltd
    • Mylan N.V.
    • Zydus Cadila
    • Horizon Therapeutics plc
    • Amneal Pharmaceuticals LLC
    • Fresenius Kabi AG
    • Vintage Labs

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Treatment
      • Market Snippet, By Route of Administration
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Technological Advancements in Still’s Disease Treatment
    • Key Developments
    • Acquisition, Collaborations & Partnerships
    • Epidemiology
    • Pipeline Analysis
    • Brand Analysis
  4. Global Still’s Disease Treatment Market, Impact of Coronavirus (Covid-19) Pandemic
    • Pre-COVID situation
    • Post-COVID demand
    • Need for Still’s Disease Treatment
    • Recommendations and Guidelines by Regulatory Bodies
  5. Global Still’s Disease Treatment Market, By Treatment, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Pain Management
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Corticosteroids
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Tocilizumab
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Canakinumab
      • Introduction    
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Anakinra
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Others
      • Introduction    
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  6. Global Still’s Disease Treatment Market, By Route of Administration , 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Injectable
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Oral
      • Introduction    
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  7. Global Still’s Disease Treatment Market, By Distribution Channel, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Hospital Pharmacies
      • Introduction    
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Online Pharmacies
      • Introduction    
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  8. Global Still’s Disease Treatment Market, By Region, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027(%)
      • Y-o-Y Growth Analysis, By Region, 2017 –2027
      • Regional Trends
    • North America
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
    • Middle East
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
  9. Competitive Landscape
    • Company Profiles
      • AB2 Bio Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Hoffmann-La Roche Ltd
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Novartis AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Swedish Orphan Biovitrum AB
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Jubilant Life Sciences Ltd
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Vintage Labs
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Hikma Pharmaceuticals PLC
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Teva Pharmaceutical Industries Ltd
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Mylan N.V.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Horizon Therapeutics plc
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Sun Pharmaceutical Industries Ltd
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Zydus Cadila
        •  Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Amneal Pharmaceuticals LLC
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Dr Reddy's Laboratories Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Fresenius Kabi AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
  10. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 26 market data tables and 28 figures on "Global Still’s Disease Treatment Market” - Forecast to 2027”

Frequently Asked Questions

The CAGR of the still’s disease treatment market is expected to be 4.49% during the forecast period (2020-2027).
The value of the global market for the still’s disease treatment is estimated to be valued at US$ 1,539.4 million in 2020.
The prominent players in still’s disease treatment market across the globe include AB2 Bio Ltd., F. Hoffmann-La Roche Ltd, Novartis AG, Swedish Orphan Biovitrum AB, Jubilant Life Sciences Ltd, Vintage Labs, Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd, Mylan N.V., Horizon Therapeutics plc, Sun Pharmaceutical Industries Ltd, Zydus Cadila, Amneal Pharmaceuticals LLC, Dr Reddy's Laboratories Ltd., and Fresenius Kabi AG.
The still’s disease treatment market is expected to be valued at US$ 2,093.8 million in 2027.
The major region in the still’s disease treatment market is Europe.
Investments in R&D and the rising prevalence of still's disease across the globe are driving growth of the market.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner